Conference Coverage
Latest News
Dec 12, 2025 | News
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
Dec 12, 2025
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
Dec 12, 2025
FDA approves first-line Zenflow system for the treatment of BPH
Dec 11, 2025
FDA approves gepotidacin for uncomplicated urogenital gonorrhea
Dec 11, 2025
Advertisement
Shorts
1:06
Aleece Fosnight, MSPAS, PA-C, on communication with patients with incontinence
10 hours ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:03
Pearls & Perspectives: Gaps in Care of Patients with Spinal Cord Injuries
a day ago
by
Amy M. Pearlman, MD
0:44
Mark D. Tyson, II, MD, MPH, highlights topline data on cretostimogene in papillary NMIBC
3 days ago
by
Mark D. Tyson, II, M.D., M.P.H.
1:04
Sameena A. Rahman, MD, on the importance of countering misinformation on GSM
3 days ago
by
Sameena A. Rahman, MD
1:08
Alexandra Sokolova, MD, on how TRIPLE-SWITCH addresses a research gap in mCSPC
4 days ago
by
Alexandra Sokolova, MD
1:09
Timothy D. Lyon, MD, on the challenges of delivering BCG at home
7 days ago
by
Benjamin P. Saylor
1:16
Arvin George, MD, on what makes the Vanquish Water Vapor System unique
8 days ago
by
Arvin K. George, MD
1:25
Sameena A. Rahman, MD, on counseling patients with GSM
9 days ago
by
Sameena A. Rahman, MD
1:59
Leila Momtazi-Mar on role of testosterone and other factors in predicting sperm retrieval success
11 days ago
by
Leila Momtazi-Mar
1:16
Angela B. Smith, MD, MS, on proactively including PROs in bladder cancer trials
11 days ago
by
Angela B. Smith, MD, MS
Dr. Laura Sena discusses ongoing trials of bipolar androgen therapy in prostate cancer
Bipolar androgen therapy is being explored in trials with enzalutamide (Xtandi), olaparib (Lynparza), and nivolumab (Opdivo), explains Laura Sena MD, PhD.
Podcasts
Videos
Urology Times Digital Edition
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
The trial will assess the effect of adding docetaxel to SOC hormone therapy plus apalutamide in mCSPC.
The phase 1 trial is assessing VIR-5500 as both a monotherapy and in combination with ARPIs in prostate cancer.
"Suctioning technology for mini-PCNL is an improvement on relying on passive outflow," says Mantu Gupta, MD.
SBRT demonstrated favorable 4-year biochemical recurrence-free survival with a manageable safety profile.
"My pragmatic takeaway is that for patients who experience spasm or leak despite anticholinergics, this is a great thing to consider," says Mark D. Tyson II, MD, MPH.
The study is assessing the safety and tolerability of the CaverSTIM device for ED after surgical removal of the prostate.
Data showed that adding niraparib to AAP significantly improved radiographic progression-free survival in this patient population.
This announcement follows positive top-line data from a phase 1b/2a clinical trial of EG110A in patients with NDO following a spinal cord injury.
Continuing Medical Education
Advertisement
All News
Advertisement
Ibrahim explains the unique challenges men face after spinal cord injury, including neurogenic erectile dysfunction, ejaculatory dysfunction, and particularly the distinctive sperm abnormalities seen in this population.
In a panel meeting convened by the FDA, experts urged the agency to revise the current classification and indication for testosterone replacement therapy in men.
Daré Bioscience said the sildenafil cream’s availability will expand to other states throughout December 2025 and early 2026.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
The approval is supported by results from the randomized ProVIDE study.
The pilot study plans to enroll patients with locally recurrent prostate cancer across clinical trial sites in the US.
The FDA has selected detalimogene voraplasmid to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program.
The phase 1 study will assess the safety and feasibility of SPECT/CT imaging with [111In]In-ART-101.
The investigators reported a high-grade CR rate at any time of 72.4% (21 of 29 patients).
DFS rate was 85.3% at 6 months (95% CI, 71.6-92.7), 74.3% at 12 months (95% CI, 59.2-84.6), and 69.2% at 18 months (95% CI, 53.4-80.6).
Advertisement
In patients with high-grade T1 disease, high-grade EFS was 100% and 3 months and at 6 months and 87.5% at 9 months.
Following treatment with SYNC-T, all bone metastases had resolved in 7 of the 13 patients.
The overall CR rate was 83.7% (95% CI, 70.3-92.7).
Forty-one of the 85 patients experienced disease persistence, progression, or recurrence.
CR at any time was 92% (23/25 patients), 84% (21/25) at 3 months, 87% (20/23) at 6 months, and 85% (17/20) at 9 months.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
5
